Latest Conference Articles

Late-breaking phase 3 data on nemolizumab monotherapy indicates substantial improvement in key primary and secondary endpoints for prurigo nodularis patients.

The Icahn investigator reviews new data suggesting ethnicity-based differences in molecular phenotype of atopic dermatitis, which may better inform treatment strategies for different populations.

Late-breaking data showed strong results for ruxolitinib cream as a treatment for vitiligo in the long-term extension of the TRuE-V1 and TRuE-V2 studies.

New phase 3 DELTA 1 trial data show the topical pan-JAK inhibitor doubled the rate of treatment success versus vehicle cream.

New late-breaking data showed positive results from the phase 2 trial on a novel septa-specific monoclonal antibody for HS patients.

Dupilumab showed strong results for uncontrolled moderate-to-severe hand and foot atopic dermatitis, meeting its primary and secondary endpoints in the trial.

New long-term extension data from the pivotal TRuE-V program show treatment continuation, as well as post-relapse re-initiation, is efficacious and safe in patients.

In this interview segment, Kwatra describes his upcoming conference presentation on prurigo nodularis and some of the biggest takeaways from his presentation.

After last year's historic approval, investigators want to learn more about their available drug regimens, as well as pediatric eligibility.

The University of Toronto expert discusses therapy switching, JAK inhibitor initiation, comorbidity cross-benefit, and more at AAD 2023.

Amid the introduction of immunosuppressant therapies and the ongoing pandemic, dermatologists find themselves guiding new decisions for patient treatment around vaccinations.

An interview segment with Lim in which he describes some key takeaways from his conference presentation on sunscreen, photoprotection, and phototherapy.

Little head-to-head data exists between JAK inhibitors and biologics, but common metrics of treatment success can help physicians navigate newer agents.

In his conference presentation ‘Phototherapy and Photoprotection,’ Lim describes some key takeaways and research on UV filter and photoprotection health effects.

The UMass Chan chair of dermatology recaps a historic year of development for the chronic disease, including the progression of even newer treatment options.

The Mount Sinai Dermatology chair reviews headlines from the 2022 meeting before sharing perspective on developing drugs and topics.

Damsky discussed his conference presentation on the application of JAK inhibitors on dermatologic conditions such as granuloma annulare and sarcoidosis.

Beyond the obvious benefits, the practice of remote and in-clinic photography is altering treatment capabilities.

The St. Jude oncologist discusses the 30-year development of pediatric melanoma interpretation.

Practicing oral hygiene improves health issues from gum disease to cardiac disease, and Lebovic believes nasal hygiene can have that impact as well.

"The anticipation would be–wash your hands, brush your teeth, clean your nose–and allow that process to help the patients who suffer from allergy symptoms," lead investigator Dr. Arman Kalmakarian says.

Gregg W. Stone, MD, discussed the 5-year findings of the COAPT trial and provided insight into the benefit of the transcatheter procedure in high-risk patients with heart failure.

At ACC 2023, Hoeper provides insight into the key efficacy findings of STELLAR and delves into the safety concerns and generalizability of sotatercept for PAH.

In an interview at ACC 2023, Safia Chatur, MD provided insight into the analysis of the PARADIGM-HF and PARAGON-HF trials, suggesting early eGFR changes should not deter continuation of sacubitril/valsartan.

In another interview segment, Castells discussed the safety profile of avapritinib for indolent systemic mastocytosis, as well as future research.

At ACC 2023, results from the RAPID-HF trial reported atrial pacing was ineffective at improving exercise capacity in patients with HFpEF and chronotropic incompetence.

Results from the phase 3 A DUE study suggest a combination of macitentan and tadalafil nearly doubled reductions in pulmonary vascular resistance in patients with PAH.

At the AAAAI 2023 Annual Meeting, Dr. Debajyoti Ghosh explains the importance of understanding the effect of phthalates, specifically di-2-ethylhexyl phthalate (DEHP).